Temperature-Sensitive Mutants of p16CDKN2 Associated with Familial Melanoma
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Altered expression or function of the p16CDKN2 tumor suppressor gene on chromosome 9p21 occurs in a wide range of human tumors, and mutations in the gene have been shown to segregate with familial predisposition to malignant melanoma. We have used a variety of assays to examine the functional properties of tumor-associated alleles, including eight premature termination mutants, eight missense mutants, and three isoforms of p16 initiated at different amino-terminal methionine codons. The amino- and carboxy-terminal domains of the protein, outside the ankyrin-like repeats, appeared to be dispensable, but the majority of the premature termination mutations led to loss of function. Of the missense mutations tested, four displayed clear loss of function whereas two behaved like the wild type under all conditions tested. The remaining two mutations, a G-to-W mutation at position 101 (Gl01W) and V126D, both of which are associated with familial melanoma, were found to be temperature sensitive for binding to Cdk4 and Cdk6 in vitro, for inhibiting cyclin D1-Cdk4 in a reconstituted pRb-kinase assay, and for increasing the proportion of G1-phase cells following transfection. These findings clarify previous disparities and argue strongly that p16CDKN2 is a bona fide tumor suppressor associated with familial melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 17×
“DISCUSSION The only known function of p16CDKN2 is to bind to Cdk4 and Cdk6 and thereby inhibit their activity as Cdks (15, 41, 48).”
BackgroundInfluentialA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899 · cited 4×
“Several groups have tried to confirm the role of p16 as a tumor suppressor by demonstrating that tumor-specific mutations in p16 affect its function (27, 30, 45, 46, 59, 61).”
BackgroundInfluentialSelf-citationGermline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“In addition, cyclin D1 expression can be activated by chromosomal translocations (14), and Cdk4 can sustain mutations that reduce its sensitivity to inhibition by p16 (60, 64).”
BackgroundGenetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752 · cited 3×
“Although there may well be an additional selection for p16 loss during the immortalization of cultured cells (16, 29, 47), there is no doubt that p16 alterations occur at significant frequencies in primary tumors (14).”
BackgroundSelf-citation
Cited by
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Self-citationThe ankyrin repeat as molecular architecture for protein recognition
Mosavi, L. K., Cammett, T. J., Desrosiers, D. C., & Peng, Z. (2004) · Protein Science · doi:10.1110/ps.03554604 · Cited by 907
Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria
Nykamp, K., Anderson, M., Powers, M., Garcia, J., Herrera, B., Ho, Y.-Y., Kobayashi, Y., Patil, N., Thusberg, J., Westbrook, M., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.37 · Cited by 762
Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
Soufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
Borg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., & Ingvar, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1260 · Cited by 345
Ezhevsky, S. A., Nagahara, H., Vocero-Akbani, A. M., Gius, D. R., Wei, M. C., & Dowdy, S. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10699 · Cited by 280
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors
Miao, L., Lin, C. M., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.017 · Cited by 264
CDKN2A Mutations in Multiple Primary Melanomas
Monzon, J., Liu, L., Brill, H., Goldstein, A. M., Tucker, M. A., From, L., McLaughlin, J., Hogg, D., & Lassam, N. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381305 · Cited by 264
INK4a‐deficient human diploid fibroblasts are resistant to RAS‐induced senescence
Brookes, S., Rowe, J., Ruas, M., Llanos, S., Clark, P. A., Lomax, M., James, M. C., Vatcheva, R., Bates, S., Vousden, K. H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf289 · Cited by 220
Self-citationParry, D., Mahony, D., Wills, K., & Lees, E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1775 · Cited by 174
Self-citationBERMAN, H., ZHANG, J., CRAWFORD, Y. G., GAUTHIER, M. L., FORDYCE, C. A., McDERMOTT, K. M., SIGAROUDINIA, M., KOZAKIEWICZ, K., & TLSTY, T. D. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.051 · Cited by 51
(1998) · doi:10.1002/(sici)1098-1004(1998)11:6
Metadata
- Authors
- Parry, D., & Peters, G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1996-07-01
- Volume
- 16
- Issue
- 7
- Pages
- 3844-3852
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2108417782
- Cited by
- 94
- References
- 12
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.